USA flag logo/image

An Official Website of the United States Government

VACCINE VECTORS TO STIMULATE MUCOSAL IMMUNITY

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
11081
Program Year/Program:
1989 / SBIR
Agency Tracking Number:
11081
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APPLIED BIOTECH CONCEPTS, INC.
25 SCIENCE PARK NEW HAVEN, CT 06511
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1989
Title: VACCINE VECTORS TO STIMULATE MUCOSAL IMMUNITY
Agency: HHS
Contract: N/A
Award Amount: $41,998.00
 

Abstract:

A MODEL WILL BE DEVELOPED TO CREATE EFFECTIVE VACCINE VECTORS THAT WILL ELICIT MUCOSAL (SECRETORY) IMMUNITY. RECOMBINANT VACCINIA VIRUS THAT EXPRESS ONE OR MORE ANTIGENSOF THE PSEUDORABIES VIRUS (PRV) WILL BE USED AS THE PROTOTYPE IN THE DESIGN OF THE FIRST-GENERATION VECTORS. THE LD50 (THE DOSE LETHAL FOR 50 PERCENT OF THE ANIMALS CHALLENGED) OF PRV IN MICE WILL FIRST BE DETERMINED AFTER INTRAPERITONEAL, ORAL, AND NASAL ADMINISTRATION OF PRV. THE DOSE DETERMINED FOR EACH ROUTE WILL THEN BE USED TO CHALLENGE MICE THAT HAVE BEEN PREVIOUSLY VACCINATED INTRAPERITONEALLY, ORALLY, OR NASALLY WITH VACCINIA/PRV RECOMBINANTS. THE RATIO OF THE NUMBER OF ANIMALS THAT SURVIVE CHALLENGE TO THOSE THAT SUCCUMB WILL INDICATE THE FEASIBILITY OF USING THIS VACCINIA/PRV SYSTEM IN THE DESIGN OF A MODEL TO TEST THE EFFICACY OF THESE VIRAL VECTORS FOR USE AS MUCOSAL VACCINES. THE DEVELOPMENT OF VACCINES THAT ARE CAPABLE OF STIMULATING SECRETORY IMMUNITY WILL BE IMPORTANT IN PROTECTING AGAINST INFECTION BY A VARIETY OF PATHOGENS WHOSE INITIAL ROUTE OF ENTRY INTO THE HOST IS VIA MUCOSAL SURFACES.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Applied Biotechnology Inc
80 Rogers St Cambridge, MA 02142

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No